Project Grant K08CA293273
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $315K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The University of Illinois was awarded a $160,330 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) with a performance period of December 1, 2024 to November 30, 2026. The project seeks to develop novel human-relevant lung adenocarcinoma models by genome editing primary human lung stem and progenitor cells, and culturing them as tumor organoids or orthotopically xenografting them into mice. The goal is to create models that more accurately reflect...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...
- The National Cancer Institute awarded a $148,050 Project Grant under the Cancer Research Manpower federal grant program (CFDA 93.398) to Weill Medical College of Cornell University. The grant supports research to study the role of the APOBEC3 family of cytosine deaminases in driving genomic instability and mutagenesis in lung cancer. The project aims to identify the specific APOBEC3 enzymes responsible for lung cancer mutagenesis and develop novel tools to measure APOBEC3 activity. This research...
- This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...
- The federal Project Grant award of $472,730.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is funding research at Weill Medical College of Cornell University to elucidate the role of the tumor suppressor KEAP1 in antitumor immunity for non-small cell lung cancer (NSCLC). The research aims to investigate how newly identified upregulated oncoproteins that are potential KEAP1 substrates contribute to the immune-evasive phenotype observed in KEAP1-mutant NSCLCs. The...
- The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon gamma (IFNγ) signaling pathway in the lung tumor microenvironment and its impact on tumor immunity. The project aims to deconvolute how various components of the IFNγ pathway, including the negative regulator SOCS1, influence immune cell infiltration and response to immune...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $147,486 to Yale University to elucidate the mechanisms underlying the progression of non-small cell lung cancer (NSCLC) to leptomeningeal disease (LMD). The primary objectives are to identify the pathophysiological mechanisms driving the progression to LMD, particularly in cases of EGFR-mutant NSCLC that become resistant to tyrosine kinase inhibitor (TKI) treatment. The research...